<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37940843</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population.</ArticleTitle><Pagination><StartPage>774</StartPage><MedlinePgn>774</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">774</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-023-08787-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While many studies on the determinants of post-COVID-19 conditions (PCC) have been conducted, little is known about the relationship between SARS-CoV-2 variants and PCC. This study aimed to assess the association between different SARS-CoV-2 variants and the probability of having PCC three months after the infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR&#x2009;=&#x2009;1.61, 95% confidence interval [CI]&#x2009;=&#x2009;1.33-1.96 and OR&#x2009;=&#x2009;1.73, 95%CI&#x2009;=&#x2009;1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thi Khanh</LastName><ForeName>Huyen Nguyen</ForeName><Initials>HN</Initials><Identifier Source="ORCID">0000-0002-6104-0319</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium. khanhhuyenhnhuph@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. khanhhuyenhnhuph@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornelissen</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanares-Zapatero</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Pauw</LastName><ForeName>Robby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Cauteren</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demarest</LastName><ForeName>Stefaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drieskens</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devleesschauwer</LastName><ForeName>Brecht</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ridder</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charafeddine</LastName><ForeName>Rana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and public health, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health and Society (IRSS), Universit&#xe9; catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>internal funding</GrantID><Agency>Sciensano</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004408" MajorTopicYN="N">Dysgeusia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37940843</ArticleId><ArticleId IdType="pmc">PMC10634063</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08787-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-023-08787-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 October 2021 [Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;49(6):1163&#x2013;86. doi: 10.1007/s15010-021-01666-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01666-x</ArticleId><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, de Maertens C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473&#x2013;87. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Global Health. 2021;6(9):e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-covid-19 Illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#x2013;32. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and Meta-analysis of one-year Follow-Up studies on Post-COVID symptoms. Pathogens. 2022;11(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Almas T, Malik J, Alsubai AK, Jawad Zaidi SM, Iqbal R, Khan K et al. Post-acute COVID-19 syndrome and its prolonged effects: an updated systematic review. Ann Med Surg (Lond). 2022:103995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197790</ArticleId><ArticleId IdType="pubmed">35721785</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting 31 Oct 2022 [Available from: https://www.ecdc.europa.eu/en/publications-data/prevalence-post-covid-19-condition-symptoms-systematic-review-and-meta-analysis.</Citation></Reference><Reference><Citation>Meurisse M, Van Oyen H, Blot K, Catteau L, Serrien B, Klamer S, et al. Evaluating methodological approaches to assess the severity of Infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. BMC Infect Dis. 2022;22(1):839. doi: 10.1186/s12879-022-07777-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07777-6</ArticleId><ArticleId IdType="pmc">PMC9651100</ArticleId><ArticleId IdType="pubmed">36368977</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet. 2022;399(10343):2263&#x2013;4. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Naucl&#xe9;r P. Post COVID-19 condition after SARS-CoV-2 Infections during the omicron surge compared with the delta, alpha, and wild-type periods in Stockholm, Sweden. J Infect Dis. 2023:jiad382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10786247</ArticleId><ArticleId IdType="pubmed">37665981</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, Kristoffersen DT, Dell&#x2019;Isola A, Kiadaliri A, Turkiewicz A, Runhaar J, et al. Post-covid medical complaints following Infection with SARS-CoV-2 omicron vs Delta variants. Nat Commun. 2022;13(1):7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Kaufmann M, Amati R, Frei A, von Wyl V, et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 Infection and prior vaccination: pooled analysis of two population-based cohorts. PLoS ONE. 2023;18(2):e0281429. doi: 10.1371/journal.pone.0281429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281429</ArticleId><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith P, Proesmans K, Van Cauteren D, Demarest S, Drieskens S, De Pauw R, et al. Post COVID-19 condition and its physical, mental and social implications: protocol of a 2-year longitudinal cohort study in the Belgian adult population. Archives of Public Health. 2022;80(1):1&#x2013;12. doi: 10.1186/s13690-022-00906-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-022-00906-2</ArticleId><ArticleId IdType="pmc">PMC9166244</ArticleId><ArticleId IdType="pubmed">35659364</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma M. COVID-19: molecular diagnostics overview. J Mol Med. 2020;98(7):947&#x2013;54. doi: 10.1007/s00109-020-01931-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-020-01931-w</ArticleId><ArticleId IdType="pmc">PMC7293435</ArticleId><ArticleId IdType="pubmed">32535768</ArticleId></ArticleIdList></Reference><Reference><Citation>Proesmans K, Hancart S, Braeye T, Klamer S, Robesyn E, Djiena A, et al. COVID-19 contact tracing in Belgium: main indicators and performance, January - September 2021. Arch Public Health. 2022;80(1):118. doi: 10.1186/s13690-022-00875-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-022-00875-6</ArticleId><ArticleId IdType="pmc">PMC9005619</ArticleId><ArticleId IdType="pubmed">35418097</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . Clinical guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5):2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciensano, Belgium. COVID-19 Epidemiological Situation [Available from: https://datastudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC.</Citation></Reference><Reference><Citation>Sciensano, RECOMMANDATIONS POUR LA S&#xc9;LECTION D&#x2019;&#xc9;CHANTILLONS EN VUE DU S&#xc9;QUEN&#xc7;AGE DU G&#xc9;NOME. COMPLET 2021 [Available from: https://covid-19.sciensano.be/sites/default/files/Covid19/20210125_RAG_Selection%20of%20samples%20for%20sequencing_FR.pdf.</Citation></Reference><Reference><Citation>(ECDC) ECfDPaC. Evaluation of the SARS-CoV-2 testing policy in Belgium from June to December 2021 2022 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-evaluation-SARS-CoV-2-testing-policy-Belgium-Feb-2022.pdf.</Citation></Reference><Reference><Citation>Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, et al. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine. 2022;40(22):3027&#x2013;37. doi: 10.1016/j.vaccine.2022.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.04.025</ArticleId><ArticleId IdType="pmc">PMC9001203</ArticleId><ArticleId IdType="pubmed">35459558</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical Computing. R Foundation for Statistical Computing, Vienna, Austria [Available from: https://www.R-project.org/.</Citation></Reference><Reference><Citation>Cole SR, Zivich PN, Edwards JK, Ross RK, Shook-Sa BE, Price JT, et al. Missing Outcome data in epidemiologic studies. Am J Epidemiol. 2023;192(1):6&#x2013;10. doi: 10.1093/aje/kwac179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwac179</ArticleId><ArticleId IdType="pmc">PMC10144620</ArticleId><ArticleId IdType="pubmed">36222655</ArticleId></ArticleIdList></Reference><Reference><Citation>Grint DJ, Wing K, Houlihan C, Gibbs HP, Evans SJW, Williamson E, et al. Severity of severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) alpha variant (B.1.1.7) in England. Clin Infect Dis. 2022;75(1):e1120&#x2013;e7. doi: 10.1093/cid/ciab754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab754</ArticleId><ArticleId IdType="pmc">PMC8522415</ArticleId><ArticleId IdType="pubmed">34487522</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M et al. Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. MedRxiv. 2021:2021.08. 15.21262077.</Citation></Reference><Reference><Citation>Canas LS, Molteni E, Deng J, Sudre CH, Murray B, Kerfoot E et al. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digit Health. 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187990</ArticleId><ArticleId IdType="pubmed">37202336</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe9;e A. Dysautonomia and implications for Anosmia in Long COVID-19 Disease. J Clin Med. 2021;10(23):5514. doi: 10.3390/jcm10235514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10235514</ArticleId><ArticleId IdType="pmc">PMC8658706</ArticleId><ArticleId IdType="pubmed">34884216</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, G&#xf3;mez-Mayordomo V, Pellicer-Valero OJ, Mart&#xed;n-Guerrero JD, et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, Alpha or Delta SARS-CoV-2 variant. Pathogens. 2022;11(7):725. doi: 10.3390/pathogens11070725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070725</ArticleId><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Association WM. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566407</ArticleId><ArticleId IdType="pubmed">11357217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>